Janssen Pharmaceutica Nv

Josh Lauring

Tongfei Wu

Dirk Brehmer

Kathryn Elizabeth Packman

Hong Xie

Nahor Haddish-Berhane

Yue Guo

Geert S J Mannens

Junguo Zhou

Hillary Joy Millar Quinn

Anthony T Greway

The present disclosure provides methods for treating a human patient diagnosed with a cancer, comprising administering a therapeutically effective amount of a PRMT5 (protein arginine methyltransferase 5) inhibitor, certain methods comprising (i) administering to the patient initial doses of at least about 0.1 mg per day of the PRMT5 inhibitor that is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharmaceutically acceptable addition salt or solvate thereof for an initial dosing period of about 5 to about 21 days; and (ii) administering to the patient subsequent doses of at least about 0.1 mg per day of the PRMT5 inhibitor for one or more subsequent dosing periods of about 5 to about 21 days each. In these methods, a first subsequent dosing period is separated in time from the initial dosing period by at least about 5 days and the subsequent dosing periods are separated in time from each other by at least about 5 days.

Methods of treating cancer using PRMT5 inhibitors

Growing community of inventors

Towson, MD, United States of America

Josh Lauring